Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ovarian recurrence

Devise a plan for the management of common complications associated with advanced and recurrent ovarian cancer. [Pg.1385]

Single-agent chemotherapy is standard practice for recurrent platinum-resistant ovarian cancer. [Pg.1385]

Since the efficacy of the agents is similar, selection of an agent for the treatment of recurrent platinum-resistant ovarian cancer depends on residual toxicities, physician preference, and patient convenience. [Pg.1385]

The three recurrent theories proposed are the incessant-ovulation hypothesis, the pituitary gonadotropin hypothesis, and the chronic inflammatory processes hypothesis.2,31 The incessant-ovulation hypothesis proposes that the pathogenesis of ovarian... [Pg.1387]

TABLE 91-3. Summary of Chemotherapy Agents Used for Second-Line Treatment of Progressive and Recurrent Platinum-Resistant Ovarian Cancer... [Pg.1393]

Provide appropriate patient education on respective chemotherapy agents that will be given for treatment of recurrent ovarian cancer. [Pg.1394]

Salom E, Almeida Z, Mirashemi R. Management of recurrent ovarian cancer evidence-based decisions. Curr Opin Oncol 2002 14 519-527. [Pg.1395]

Salzberg M, Thurlimann B, Bonnefois H, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005 68 293-298. [Pg.1395]

CA 125 is a widely used cancer marker for monitoring treatment responses and detecting disease recurrences in patients with ovarian cancer. Generally, the CA 125 cutoff value of 35 U/ml is used for the mean value in normal women. It has been shown that values above and below this cutoff correlate reasonably well with the regression or progression of disease (6, 7). [Pg.194]

Ninety-five percent patients monitored for recurrence show CA 125 concentrations greater than 35 U/ml and residual ovarian carcinoma. However, a negative result is not conclusive because half of the patients with negative results have microscopic residual carcinoma. Therefore, it is essential to have a second-look procedure in order to rule out residual carcinoma. Postsurgical monitoring of patients... [Pg.194]

Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17 360-369... [Pg.19]

Cordon, A.N. et al.. Recurrent epithelial ovarian carcinoma a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, /. Clin. Oncol., 19, 3312-3322,2001. [Pg.456]

Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001 81 206. [Pg.47]

Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G Tisi G Katsaros D, Lhomme C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, GuastaUa JP. (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 21 759-765. [Pg.167]

Audeh MW, Carmichael J, Penson RT et al (2010) Oral polyADP-ribose polymerase inhibitor olaparib in patients with BRCAl or BRCA2 mutations and recurrent ovarian cancer a proof-of- concept trial. Lancet 376 245-251... [Pg.135]

Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative hreast cancer a phase 2, multicentre, open-lahel, non-ran-domised study. Lancet Oncol 12 852-861... [Pg.136]

Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCAI or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30 372-379... [Pg.136]

Vasey, RA., L.N. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, D.H. Kirn, V. O Neill, N. Siddiqui, M.V. Seiden, and S.B. Kaye, Phase trial of intraperitoneal injection of the ElB-55-kd-gene-deleted adenovirus ONYX-015 (dll520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol, 2002. 20(6) 1562-9. [Pg.424]

Megestrol acetate has also proved of value in patients with metastatic prostatic cancer, epithelial ovarian cancer, or malignant melanoma and is therefore used in both sexes. The adverse effects are very similar in men to those seen with oncological doses in women loss of libido and potency is likely to occur in male patients. In one clinical study of 43 men with recurrent and metastatic cancer of the prostate given megestrol acetate 160 mg/ day orally, five developed a symptomatic rise in liver... [Pg.290]

A variety of new molecules either in combination with liposomal doxorubicin or not are in development at the moment [457]. For example, a phase III study will be conducted to test the efficacy and safety of pattupilone versus PEG-liposomal DXR in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian, or primary peritoneal cancer. A phase III randomized study of Telcyta with Doxil/Caelyx versus Doxil/Caelyx has been planned in patients with platinum-refractory or platinum-resistant ovarian cancer. A phase II study relevant to side effects and best dose of ixabepilone combined with liposomal DXR will be assessed in patients with advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer or metastatic breast cancer. [Pg.504]

Katsaros, D., Oletti, M. V., Rigault de la Longrais, I. A., Ferrero, A., Celano, A., Fracchioli, S., Donadio, M., Passera, R., Cattel, L., and Bumma, C. (2005), Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma, Ann Oncol, 16,300-306. [Pg.532]

Doxorubicin Doxil/Caelyx MPEG-DSPE, HSPC, cholesterol, ammonium sulfate, sucrose, histidine Refractory Kaposi s sarcoma ovarian cancer recurrent breast cancer Alza/SP Europe... [Pg.1263]

Albuquerque, K.V., Singla, R., Potkul, R.K., Smith, D.M., Creech, S., Lo, S., Emami, B. (2005). Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. Gynecol. Oncol. 96 701-4. [Pg.391]

Recurrent ovarian cancer Infectious disease Fungal infection, AIDS Ophthalmic disease... [Pg.282]

See other pages where Ovarian recurrence is mentioned: [Pg.437]    [Pg.86]    [Pg.760]    [Pg.1388]    [Pg.1389]    [Pg.1391]    [Pg.1392]    [Pg.1392]    [Pg.1392]    [Pg.194]    [Pg.194]    [Pg.195]    [Pg.487]    [Pg.340]    [Pg.713]    [Pg.170]    [Pg.356]    [Pg.190]    [Pg.590]    [Pg.282]    [Pg.599]    [Pg.154]    [Pg.504]    [Pg.86]    [Pg.386]   
See also in sourсe #XX -- [ Pg.251 , Pg.252 ]



SEARCH



Ovarian cancer recurrent chemotherapy

Ovarian cancer, recurrent

Recurrence

© 2024 chempedia.info